Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Relapsed/refractory Multiple Myeloma (MM) is an incurable disorder with a poor prognosis.
Carfilzomib is a novel proteasome inhibitor with activity in this setting. Panobinostat is a
pan-deacetylase inhibitor which has shown synergistic cytotoxicity in vitro and in vivo with
proteasome inhibitors. The combination should enhance the activity of both agents against
myeloma cells. In Phase I, the optimal doses of the combination of carfilzomib and
panobinostat will be determined. Assuming this combination is feasible, the Phase II portion
will proceed using the doses determined in Phase I.